Pim-2 phosphorylation of p21Cip1/WAF1 enhances its stability and inhibits cell proliferation in HCT116 cells

International Journal of Biochemistry and Cell Biology

Volumn 42, Issue 6, 2010, Pages 1030-1038

  Wang, Zeping ^a   Zhang, Yandong ^a   Gu, Juan Jenny ^a   Davitt, Christine ^a   Reeves, Raymond ^a   Magnuson, Nancy S ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Cell proliferation; P21Cip1 WAF1; Phosphorylation; Pim 2; Protein stability

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; ONCOPROTEIN; PROTEIN PIM 2; SMALL INTERFERING RNA; THREONINE; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN HCT116; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; RNA INTERFERENCE;

ACTIVE TRANSPORT, CELL NUCLEUS; CELL NUCLEUS; CELL PROLIFERATION; CLONING, MOLECULAR; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HCT116 CELLS; HUMANS; PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING; TRANSGENES;

EID: 77953806550     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2010.03.012     Document Type: Article

References (61)

1. Abbas T., Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009, 9:400-414.
2. Abukhdeir A.M., Park B.H. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med 2008, 10:e19.
3. Akue-Gedu R., Rossignol E., Azzaro S., Knapp S., Filippakopoulos P., Bullock A.N., et al. Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors. J Med Chem 2009, 52:6369-6381.
4. Allen J.D., Berns A. Complementation tagging of cooperating oncogenes in knockout mice. Semin Cancer Biol 1996, 7:299-306.
5. Allen J.D., Verhoeven E., Domen J., d.van V., Berns A. Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene 1997, 15:1133-1141.
6. Amaravadi R., Thompson C.B. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 2005, 115:2618-2624.
7. Amson R., Sigaux F., Przedborski S., Flandrin G., Givol D., Telerman A. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci USA 1989, 86:8857-8861.
8. Asada M., Yamada T., Ichijo H., Delia D., Miyazono K., Fukumuro K., et al. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J 1999, 18:1223-1234.
9. Bohensky J., Shapiro I.M., Leshinsky S., Watanabe H., Srinivas V. PIM-2 is an independent regulator of chondrocyte survival and autophagy in the epiphyseal growth plate. J Cell Physiol 2007, 213:246-251.
10. Breuer M.L., Cuypers H.T., Berns A. Evidence for the involvement of pim-2, a new common proviral insertion site, in progression of lymphomas. EMBO J 1989, 8:743-748.
11. Brown J.P., Wei W., Sedivy J.M. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 1997, 277:831-834.
12. Cazzalini O., Scovassi A.I., Savio M., Stivala L.A., Prosperi E. Multiple roles of the cell cycle inhibitor p21(CDKN1A) in the DNA damage response. Mutat Res 2010.
13. Chen J.L., Limnander A., Rothman P.B. Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene. Blood 2008, 111:1677-1685.
14. Chen L.S., Redkar S., Bearss D., Wierda W.G., Gandhi V. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2009, 114:4150-4157.
15. Chen X.P., Losman J.A., Cowan S., Donahue E., Fay S., Vuong B.Q., et al. Pim serine/threonine kinases regulate the stability of Socs-1 protein. Proc Natl Acad Sci USA 2002, 99:2175-2180.
16. Child E.S., Mann D.J. The intricacies of p21 phosphorylation: protein/protein interactions, subcellular localization and stability. Cell Cycle 2006, 5:1313-1319.
17. Claudio J.O., Masih-Khan E., Tang H., Goncalves J., Voralia M., Li Z.H., et al. A molecular compendium of genes expressed in multiple myeloma. Blood 2002, 100:2175-2186.
18. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?. Trends Cell Biol 2003, 13:65-70.
19. Dai H., Li R., Wheeler T., d.Diaz V., Frolov A., Tahir S., et al. Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate 2005, 65:276-286.
20. Dhanasekaran S.M., Barrette T.R., Ghosh D., Shah R., Varambally S., Kurachi K., et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001, 412:822-826.
21. Dotto G.P. p21(WAF1/Cip1): more than a break to the cell cycle?. Biochim Biophys Acta 2000, 1471:M43-M56.
22. Eichmann A., Yuan L., Breant C., Alitalo K., Koskinen P.J. Developmental expression of pim kinases suggests functions also outside of the hematopoietic system. Oncogene 2000, 19:1215-1224.
23. Fox C.J., Hammerman P.S., Cinalli R.M., Master S.R., Chodosh L.A., Thompson C.B. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev 2003, 17:1841-1854.
24. Fox C.J., Hammerman P.S., Thompson C.B. The Pim kinases control rapamycin-resistant T cell survival and activation. J Exp Med 2005, 201:259-266.
25. Gartel A.L. The conflicting roles of the cdk inhibitor p21(CIP1/WAF1) in apoptosis. Leuk Res 2005, 29:1237-1238.
26. Gartel A.L. p21(WAF1/CIP1) and cancer: a shifting paradigm?. Biofactors 2009, 35:161-164.
27. Gartel A.L., Radhakrishnan S.K. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 2005, 65:3980-3985.
28. Gartel A.L., Serfas M.S., Tyner A.L. p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med 1996, 213:138-149.
29. Gartel A.L., Tyner A.L. Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res 1999, 246:280-289.
30. Gartel A.L., Tyner A.L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002, 1:639-649.
31. Hammerman P.S., Fox C.J., Cinalli R.M., Xu A., Wagner J.D., Lindsten T., et al. Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kappaB activation. Cancer Res 2004, 64:8341-8348.
32. Harper J.W., Elledge S.J., Keyomarsi K., Dynlacht B., Tsai L.H., Zhang P., et al. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 1995, 6:387-400.
33. Kashiwagi M., Ohba M., Watanabe H., Ishino K., Kasahara K., Sanai Y., et al. PKCeta associates with cyclin E/cdk2/p21 complex, phosphorylates p21 and inhibits cdk2 kinase in keratinocytes. Oncogene 2000, 19:6334-6341.
34. Kim G.Y., Mercer S.E., Ewton D.Z., Yan Z., Jin K., Friedman E. The stress-activated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phosphorylation. J Biol Chem 2002, 277:29792-29802.
35. LaBaer J., Garrett M.D., Stevenson L.F., Slingerland J.M., Sandhu C., Chou H.S., et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev 1997, 11:847-862.
36. Laird P.W., van der Lugt N.M., Clarke A., Domen J., Linders K., McWhir J., et al. In vivo analysis of Pim-1 deficiency. Nucleic Acids Res 1993, 21:4750-4755.
37. Lee S., Helfman D.M. Cytoplasmic p21Cip1 is involved in Ras-induced inhibition of the ROCK/LIMK/cofilin pathway. J Biol Chem 2004, 279:1885-1891.
38. Li Y., Dowbenko D., Lasky L.A. AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J Biol Chem 2002, 277:11352-11361.
39. Li Y.Y., Wang Y.Y., Taniguchi T., Kawakami T., Baba T., Ishibashi H., et al. Identification of stemonamide synthetic intermediates as a novel potent anti-cancer drug with an apoptosis-inducing bility. Int J Cancer 2009.
40. Lin Y.W., Beharry Z.M., Hill E.G., Song J.H., Wang W., Xia Z., et al. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood 2010, 115:824-833.
41. Macdonald A., Campbell D.G., Toth R., McLauchlan H., Hastie C.J., Arthur J.S. Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. BMC Cell Biol 2006, 7:1.
42. Mattiussi S., Turrini P., Testolin L., Martelli F., Zaccagnini G., Mangoni A., et al. p21(Waf1/Cip1/Sdi1) mediates shear stress-dependent antiapoptotic function. Cardiovasc Res 2004, 61:693-704.
43. Mikkers H., Nawijn M., Allen J., Brouwers C., Verhoeven E., Jonkers J., et al. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 2004, 24:6104-6115.
44. Mumenthaler S.M., Ng P.Y., Hodge A., Bearss D., Berk G., Kanekal S., et al. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther 2009, 8:2882-2893.
45. Peng C., Knebel A., Morrice N.A., Li X., Barringer K., Li J., et al. Pim kinase substrate identification and specificity. J Biochem 2007, 141:353-362.
46. Perez-Tenorio G., Berglund F., Esguerra M.A., Nordenskjold B., Rutqvist L.E., Skoog L., et al. Cytoplasmic p21WAF1/CIP1 correlates with Akt activation and poor response to tamoxifen in breast cancer. Int J Oncol 2006, 28:1031-1042.
47. Qian K., Wang L., Cywin C.L., Farmer B.T., Hickey E., Homon C., et al. Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode. J Med Chem 2009, 52:1814-1827.
48. Rossig L., Jadidi A.S., Urbich C., Badorff C., Zeiher A.M., Dimmeler S. Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells. Mol Cell Biol 2001, 21:5644-5657.
49. Segrelles C., Moral M., Lara M.F., Ruiz S., Santos M., Leis H., et al. Molecular determinants of Akt-induced keratinocyte transformation. Oncogene 2006, 25:1174-1185.
50. Sheaff R.J., Singer J.D., Swanger J., Smitherman M., Roberts J.M., Clurman B.E. Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination. Mol Cell 2000, 5:403-410.
51. Suzuki A., Kawano H., Hayashida M., Hayasaki Y., Tsutomi Y., Akahane K. Procaspase 3/p21 complex formation to resist fas-mediated cell death is initiated as a result of the phosphorylation of p21 by protein kinase A. Cell Death Differ 2000, 7:721-728.
52. Tao Z.F., Hasvold L.A., Leverson J.D., Han E.K., Guan R., Johnson E., et al. Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases. J Med Chem 2009, 52:6621-6636.
53. van der Lugt N.M., Domen J., Verhoeven E., Linders K., van der G.H., Allen J., et al. Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2. EMBO J 1995, 14:2536-2544.
54. van Lohuizen M., Verbeek S., Krimpenfort P., Domen J., Saris C., Radaszkiewicz T., et al. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 1989, 56:673-682.
55. Waga S., Hannon G.J., Beach D., Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994, 369:574-578.
56. Wang Z., Bhattacharya N., Weaver M., Petersen K., Meyer M., Gapter L., et al. Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci 2001, 2:167-179.
57. Xia W., Chen J.S., Zhou X., Sun P.R., Lee D.F., Liao Y., et al. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res 2004, 10:3815-3824.
58. Yan B., Zemskova M., Holder S., Chin V., Kraft A., Koskinen P.J., et al. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem 2003, 278:45358-45367.
59. Yoshida S., Kaneita Y., Aoki Y., Seto M., Mori S., Moriyama M. Identification of heterologous translocation partner genes fused to the BCL6 gene in diffuse large B-cell lymphomas: 5'-RACE and LA-PCR analyses of biopsy samples. Oncogene 1999, 18:7994-7999.
60. Zhang Y., Wang Z., Magnuson N.S. Pim-1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol Cancer Res 2007, 5:909-922.
61. Zhou B.P., Liao Y., Xia W., Spohn B., Lee M.H., Hung M.C. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 2001, 3:245-252.